ORIC Pharmaceuticals General and Administrative Expenses | ORIC

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses ORIC Pharmaceuticals

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
33.2 M	28.8 M	25.6 M	25.1 M	22 M	13.4 M	5.72 M	3.34 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
33.2 M	3.34 M	19.7 M

Quarterly General and Administrative Expenses ORIC Pharmaceuticals

2026-Q2	2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
9 M	8.18 M	7.9 M	8.52 M	8.08 M	-	7.12 M	7.08 M	7.03 M	-	6.29 M	6.2 M	6.16 M	-	5.97 M	6.86 M	6.43 M	-	5.56 M	5.54 M	4.86 M	-	3.8 M	3.4 M	1.92 M	-	1.46 M	1.32 M	1.13 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
9 M	1.13 M	5.64 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
Celsion Corporation CLSN	6.87 M	-	-6.63 %	$ 13.9 M	USA
FSD Pharma HUGE	9.05 M	-	5743.5 %	$ 69.7 M	Canada
Qilian International Holding Group Limited QLI	17.5 M	-	-6.08 %	$ 184 M	China
Happiness Biotech Group Limited HAPP	2.31 M	-	1.35 %	$ 17.8 M	China
Synthetic Biologics SYN	15.4 M	-	1.32 %	$ 16.2 M	USA
Dynavax Technologies Corporation DVAX	170 M	-	-	$ 2.02 B	USA
BioXcel Therapeutics BTAI	20.5 M	$ 1.19	5.31 %	$ 14.5 M	USA
Burford Capital Limited BUR	38.4 M	$ 4.37	0.23 %	$ 958 M	Britain
I-Mab IMAB	453 M	-	-	$ 866 M	China
BeyondSpring BYSI	4.56 M	$ 0.84	34.27 %	$ 34.5 M	USA
AgeX Therapeutics AGE	11 M	-	-10.17 %	$ 12.2 K	USA
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	16.2 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	5.49 M	-	-13.47 %	$ 169 M	France
Cerus Corporation CERS	80.9 M	$ 2.98	4.93 %	$ 568 M	USA
Compugen Ltd. CGEN	8.89 M	$ 2.41	4.17 %	$ 225 M	Israel
CureVac N.V. CVAC	69.7 M	-	-	$ 867 M	Germany
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Athira Pharma ATHA	16.7 M	-	-	$ 269 M	USA
BiondVax Pharmaceuticals Ltd. BVXV	24.5 M	-	0.74 %	$ 768 M	Israel
Abcam plc ABCM	224 M	-	-	$ 4.9 B	Britain
Завод ДИОД DIOD	19.7 M	-	-	-	Russia
Galera Therapeutics GRTX	5.69 M	-	-32.59 %	$ 7.61 M	USA
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
Hepion Pharmaceuticals HEPA	3.32 M	-	-18.79 %	$ 39.3 K	USA
ARCA biopharma ABIO	21.4 M	-	1052.0 %	$ 415 M	USA
MorphoSys AG MOR	65.8 M	-	2.43 %	$ 254 M	Germany
Champions Oncology CSBR	11.2 M	$ 5.1	2.63 %	$ 70.5 M	USA
Affimed N.V. AFMD	24.7 M	-	-34.95 %	$ 21.5 M	Germany
AnPac Bio-Medical Science Co., Ltd. ANPC	7.25 M	-	-1.58 %	$ 28.1 M	China
Celyad Oncology SA CYAD	10.5 M	-	-	$ 12.5 M	Belgium
Adial Pharmaceuticals ADIL	5.18 M	$ 3.98	1.86 %	$ 2.66 M	USA
Generation Bio Co. GBIO	37.8 M	-	-	$ 344 M	USA
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
AnaptysBio ANAB	50.7 M	$ 58.47	4.37 %	$ 1.68 B	USA
Anika Therapeutics ANIK	49.1 M	$ 21.5	1.56 %	$ 308 M	USA
Cyclacel Pharmaceuticals CYCCP	7.72 M	-	-4.36 %	$ 27 M	USA
Gracell Biotechnologies GRCL	139 M	-	-	$ 3.37 B	China
Aurinia Pharmaceuticals AUPH	102 M	$ 15.47	1.91 %	$ 2.08 B	Canada
GlycoMimetics GLYC	25.4 M	-	9357.83 %	$ 1.01 B	USA
Aeterna Zentaris AEZS	10.1 M	-	5.93 %	$ 314 M	Canada
AVROBIO AVRO	20.5 M	-	1083.1 %	$ 745 M	USA
BeiGene, Ltd. BGNE	2.08 B	-	0.49 %	$ 251 B	Cayman-islands
Bicycle Therapeutics plc BCYC	79.4 M	$ 3.9	0.24 %	$ 270 M	Britain
Beam Therapeutics BEAM	114 M	$ 26.75	0.91 %	$ 2.65 B	USA
AIkido Pharma AIKI	23.8 M	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
BioMarin Pharmaceutical BMRN	1.15 B	$ 67.36	0.99 %	$ 12.9 B	USA
Aptose Biosciences APTO	13.4 M	-	-45.71 %	$ 1.2 M	Canada